Pfizer and BioNTech said Wednesday that a final data analysis found their coronavirus vaccine was 95% effective in preventing Covid-19 and, in addition, appeared to fend off severe disease.
The vaccine, called BNT162b2, was highly effective against the virus 28 days after the first dose, and its effectiveness was consistent across all ages, races and ethnicities, the drugmakers said. Additionally, the elderly, who are seen as at high risk of severe illness from Covid-19, saw vaccine effectiveness of more than 94%, they added.
Pfizer said it plans to submit an application for emergency use authorization to the Food and Drug Administration “within days.” Pfizer CEO Albert Bourla said at Tuesday’s New York Times Dealbook conference that the company had accumulated enough safety data needed to submit the vaccine for review.
Medical experts note it remains unclear how long the vaccines will provide immunity and whether or how often people may need periodic booster shots.
Reference: CNBC
Thai
Eng